A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2018
At a glance
- Drugs Paclitaxel (Primary) ; Sapanisertib (Primary) ; Serabelisib (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 16 Mar 2018 Planned End Date changed from 31 Aug 2018 to 30 Sep 2019.
- 16 Mar 2018 Planned primary completion date changed from 31 Aug 2018 to 28 Feb 2019.
- 11 May 2017 Planned End Date changed from 1 Dec 2018 to 31 Aug 2018.